Global Anterior Horn Cell Disease Market
시장 규모 (USD 10억)
연평균 성장률 :
%
![Chart Image](/assets/images/barChartImage.webp)
![]() |
2023 –2030 |
![]() |
USD 0.70 Billion |
![]() |
USD 1.00 Billion |
![]() |
|
![]() |
|
>Global Anterior Horn Cell Disease Market, By Drug Type (Riluzole, Edaravone (Radicava), Glutamate Receptor Antagonist and Others), Disease Type (Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Multifocal Motor Neuropathy and Others), Diagnosis (EMG/NCS, Serum and Urine Electrophoresis, Serum Immunoelectrophoresis, Quantitative Immunoglobulins, Anti-GM1 Antibody Levels), Treatment Type (Neurotherapy, Chemotherapy, Cell Therapy and Others), Route of Administration (Oral, Injection, Transdermal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Anterior Horn Cell Disease Market Analysis and Size
The anterior horn cell disease market is expected to witness significant growth during the forecast period. Disorders of the anterior horn cell (AHC) can either be acquired or inherited. The increase in the geriatric population are vulnerable to disease globally, acts as one of the major factors driving the growth of the market. The increase in the R&D activities by the pharmaceutical and biotechnology companies to improve the treatment and adoption of lifestyle alterations such as unhealthy eating habits, increased stress and unhealthy eating habits expand the market growth.
Data Bridge Market Research analyses a growth rate in the anterior horn cell disease market in the forecast period 2023-2030. The expected CAGR of anterior horn cell disease market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 0.70 billion in 2022, and it would grow upto USD 1 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anterior Horn Cell Disease Market Scope and Segmentation
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Years |
2021 (Customizable to 2015 - 2020) |
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
Segments Covered |
Drug Type (Riluzole, Edaravone (Radicava), Glutamate Receptor Antagonist and Others), Disease Type (Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Multifocal Motor Neuropathy and Others), Diagnosis (EMG/NCS, Serum and Urine Electrophoresis, Serum Immunoelectrophoresis, Quantitative Immunoglobulins, Anti-GM1 Antibody Levels), Treatment Type (Neurotherapy, Chemotherapy, Cell Therapy and Others), Route of Administration (Oral, Injection, Transdermal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) |
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Sanofi (France), Novartis AG (Switzerland), Mitsubishi Chemical Group Corporation.(Japan), BrainStorm Cell Limited (U.S.)., Ionis Pharmaceuticals (U.S.), Genervon Biopharmaceuticals, LLC (U.S.)., Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Treeway B.V. (Netherlands), CYTOKINETICS (U.S.), AB Science (France), ADVANZ PHARMA (U.K.), Biogen (U.S.), Orphazyme (U.S.), KRIGLE PHARMA, INC (Japan), Aquestive Therapeutics, Inc (U.S.), Apotex Inc (Canada) |
Market Opportunities |
|
Market Definition
Anterior horn disease is a medical disorder affecting the spinal cord's anterior horn containing the motor neurons that are highly responsible for body muscles. Spinal muscular atrophy, progressive muscular atrophy, poliomyelitis, and amyotrophic lateral sclerosis are some of the major diseases that are often sub-divided under anterior horn. This disease involves selective involvement of muscles.
Anterior Horn Cell Disease Market Dynamics
Drivers
- Increase in Ageing Population
Numerous studies have shown that elderly population is more susceptible to suffer from this disease. According to the Aging World reports from 2015, there were about 562 million people 65 and older globally, which increased the disease's incidence and expanded the market's growth.
- Increase In The Number Of R&D Activities
The market's growth is pushed by the increase in the number of R&D activities. This will provide much beneficial opportunities for the global anterior horn cell disease market. Government is funding many of the research projects and launches to encourage researchers and pharmaceutical companies for the development of novel medicines
Opportunities
- Wide Availability Of Diagnostic Methods
The increasing availability of several diagnostic methods are increasing the market growth. Diagnostic testing for this condition includes serum immunoelectrophoresis, EMG/NCS, quantitative immunoglobulins, serum and urine electrophoresis, and anti-GM1 antibody levels. Thus, all these unique and different methods create opportunities for the market growth.
Restraints/Challenges
- Lack Of Skilled Professionals
The lack of healthcare professionals who cannot identify the disease and state the underlying treatments could decrease the market's growth during a forecast period 2023-2030.
- Unavailability of Appropriate Treatments
To treat rare conditions, at times all treatments are not available, mainly in the under-developed countries. The severe patients’ needs to be treated with the advanced specific techniques but these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This anterior horn cell disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anterior horn cell disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Anterior Horn Cell Disease Market Scope
The anterior horn cell disease market is segmented on the basis of drug type, disease type, diagnosis, treatment type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Riluzole
- Edaravone
- Glutamate Receptor Antagonist
- Others
Disease Type
- Amyotrophic Lateral Sclerosis
- Spinal Muscular Atrophy
- Multifocal Motor Neuropathy
- Others
Diagnosis
- EMG/NCS
- Serum and Urine Electrophoresis
- Serum Immunoelectrophoresis
- Quantitative Immunoglobulins
- Anti-GM1 Antibody Levels
Treatment Type
- Neurotherapy
- Chemotherapy
- Cell Therapy
- Others
Route of Administration
- Oral
- Injection
- Transdermal
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Anterior Horn Cell Disease Market Regional Analysis/Insights
The anterior horn cell disease market is analysed and market size insights and trends are provided by drug type, disease type, diagnosis, treatment type, route of administration, end-user, distribution channel as referenced above.
The major countries covered in the anterior horn cell disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the prevalence of motor neuron diseases and well-developed healthcare infrastructure within the region.
Asia-Pacific is considered to have the most lucrative period because of the developing healthcare facilities, large number of manufacturers and government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anterior Horn Cell Disease Market Share Analysis
The anterior horn cell disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anterior horn cell disease market.
Key players operating in the anterior horn cell disease market include:
- Sanofi (France)
- Novartis AG (Switzerland)
- Mitsubishi Chemical Group Corporation.(Japan)
- BrainStorm Cell Limited (U.S.)
- Ionis Pharmaceuticals (U.S.)
- Genervon Biopharmaceuticals, LLC (U.S.)
- Bausch Health Companies Inc. (Canada)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Treeway B.V. (Netherlands)
- CYTOKINETICS (U.S.)
- AB Science (France)
- ADVANZ PHARMA (U.K.)
- Biogen (U.S.)
- Orphazyme (U.S.)
- KRIGLE PHARMA, INC (Japan)
- Aquestive Therapeutics, Inc (U.S.)
- Apotex Inc (Canada)
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.